Johnson & Johnson (NYSE: JNJ) has released long-term data from the Phase I/II MonumenTAL-1 study of Talvey (talquetamab-tgvs).
The results demonstrated that patients with relapsed or refractory multiple myeloma maintained high overall response rates and durable responses.
Presented at the 2024 European Hematology Association (EHA) congress, the data showed a median duration of response (DOR) of 17.5 months in the biweekly cohort, while the weekly cohort had a median DOR of 9.5 months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze